Paxman publishes newsletter on that scalp cooling is now recommended in ESMO’s European clinical practical guidelines for cancer treatments
18 december, 2020
Today, Paxman publishes the December issue of its newsletter aimed at shareholders, investors and other interested parties.
This issue highlights that ESMO, the leading European professional organisation for medical oncology, has updated its clinical practical guidelines to include a category IIB recommendation for scalp cooling to prevent hair loss in chemotherapy patients.
The newsletter also includes information on an order for 10 scalp cooling systems to Italy, that a clinical study with Paxman’s scalp cooling has now been initiated in South Korea, that the company’s scalp cooling is receiving nationwide media coverage in Brazil, and other stories.
To read the newsletter and subscribe for upcoming issues, follow this link:http://bit.ly/paxdec20en
PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
Contacts
Richard Paxman, CEO Tel: +44 7968 020641 Email: richard@paxmanscalpcooling.com www.paxman.se
About Us
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).
The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.
Attachments
Paxman publishes newsletter on that scalp cooling is now recommended in ESMO’s European clinical practical guidelines for cancer treatments
Ämnen i artikeln
Paxman publishes newsletter on that scalp cooling is now recommended in ESMO’s European clinical practical guidelines for cancer treatments
18 december, 2020
Today, Paxman publishes the December issue of its newsletter aimed at shareholders, investors and other interested parties.
This issue highlights that ESMO, the leading European professional organisation for medical oncology, has updated its clinical practical guidelines to include a category IIB recommendation for scalp cooling to prevent hair loss in chemotherapy patients.
The newsletter also includes information on an order for 10 scalp cooling systems to Italy, that a clinical study with Paxman’s scalp cooling has now been initiated in South Korea, that the company’s scalp cooling is receiving nationwide media coverage in Brazil, and other stories.
To read the newsletter and subscribe for upcoming issues, follow this link:http://bit.ly/paxdec20en
PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
Contacts
Richard Paxman, CEO Tel: +44 7968 020641 Email: richard@paxmanscalpcooling.com www.paxman.se
About Us
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).
The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.
Attachments
Paxman publishes newsletter on that scalp cooling is now recommended in ESMO’s European clinical practical guidelines for cancer treatments
Ämnen i artikeln
-1-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-992x558.jpg&w=3840&q=75)